RxDoctor Payments Data

Phuc Tran, MD

Hospitalist · Jacksonville, FLNPI 1033185400

Payments from drug & device makers

$497in general payments, 2019–2025

Across 9 payments — averaging $55.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$167
  • Cvrx, Inc.$126
  • Medtronic$89
  • Otsuka America Pharmaceutical, Inc.$41
  • Boston Scientific$27
  • Johnson & Johnson$24
  • plus $23 from 1 others

What the payments were for

  • Food & beverage$497100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$497 in reported general payments places this provider in the 70th percentile of 1,570 hospitalist providers in Florida.

See all hospitalist providers in Florida

Medicare billing

Part B allowed, 2024
$310,111
Medicare patients
826
Services billed
3,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban410$135,034
IngrezzaValbenazine Tosylate21$73,660
NuedextaDextromethorphan Hbr/Quinidine87$63,045
XifaxanRifaximin50$61,475
DescovyEmtricitabine/Tenofov Alafenam14$32,640
TivicayDolutegravir Sodium14$29,998
TradjentaLinagliptin85$25,677
EntrestoSacubitril/Valsartan55$17,905
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,790
JardianceEmpagliflozin45$14,695
Linezolid15$14,200
Spiriva RespimatTiotropium Bromide23$12,318
SymbicortBudesonide/Formoterol Fumarate41$10,627
Atorvastatin Calcium568$10,573
VraylarCariprazine Hcl13$9,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonRisperdal Consta, Xarelto$24$17,80339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,570 hospitalist providers in Florida.

Other hospitalist in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →